Study of MB07811 in Subjects With Hypercholesterolemia
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
A Phase 2 randomized, placebo controlled study assessing the efficacy, safety, and
tolerability of MB07811 given orally to subjects with primary hypercholesterolemia for 12
weeks followed by a 6-week off drug phase.